Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis
5 affiliations
- 1Institute of Health Sciences, Federal University of Bahia
- 2SOS Immunologia delle Malattie Rare e dei Trapianti, SOD Clinica Medica, Dipartimento di Medicina Interna, Azienda Ospedaliero Universitaria delle Marche
- 3Department of Clinical and Molecular Sciences, Marche Polytechnic University
- 4Reichman University
- 5Center for Autoimmune Diseases, Sheba Medical Center
Abstract
Background: Systemic sclerosis (SSc) is a complex autoimmune disease mainly characterized by progressive fibrosis affecting the skin and internal organs. Although several immunosuppressive and targeted therapies are currently available, many patients continue to experience refractory manifestations. Intravenous immunoglobulin (IVIG) has been increasingly used as an adjunctive treatment in selected cases; however, its efficacy across different disease manifestations remains incompletely defined.
Objective: To systematically evaluate the efficacy and safety of IVIG in patients with systemic sclerosis and to quantitatively synthesize available evidence regarding its effects on skin involvement, gastrointestinal manifestations, and inflammatory myopathy.
Methods: A systematic review and meta-analysis were conducted according to PRISMA 2020 guidelines. MEDLINE/PubMed, Embase, LILACS, and the Cochrane Library were searched from January 1966 to May 2026. Studies evaluating IVIG in adult patients with systemic sclerosis were included. Randomized controlled trials, observational cohorts, pilot studies, and case series were eligible. Quantitative synthesis was performed using random-effects models and standardized mean differences (SMDs) with 95% confidence intervals (CIs).
Results: Eleven studies were included in the systematic review. Six studies provided sufficient quantitative data for the meta-analysis of skin involvement, three for gastrointestinal outcomes, and two for muscle outcomes. The most common indications for IVIG therapy were cutaneous fibrosis, inflammatory myopathy, gastrointestinal involvement, and refractory musculoskeletal manifestations. Meta-analysis demonstrated a significant improvement in skin involvement assessed by the modified Rodnan Skin Score (SMD −0.59, 95% CI −0.95 to −0.22; p = 0.0019; I ² = 78.0%). Gastrointestinal manifestations also improved significantly (SMD −0.73, 95% CI −1.16 to −0.29; p = 0.0012; I ² = 0%). For inflammatory myopathies, a limited quantitative synthesis of two studies showed a significant reduction in creatinekinase levels (SMD −0.53, 95% CI −0.80 to −0.26; p < 0.001). Across studies, IVIG was well tolerated, and serious adverse events were uncommon.
Conclusion: IVIG was associated with improvements in several clinical outcomes, particularly in observational studies, including skin fibrosis, gastrointestinal manifestations, and inflammatory myopathies. However, the only randomized placebo-controlled trial did not demonstrate significant short-term improvement in skin involvement at its primary endpoint. The available evidence suggests a potential adjunctive role for IVIG in selected patients.
Related
- Comparative efficacy and safety of systemic therapies for moderate-to-severe atopic dermatitis in adults: a systematic review of randomized controlled trials
- Cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials
- Salivary gland and hand involvement in Systemic sclerosis: A cross-sectional ultrasound and radiographic study.
- Spatial proteomic profiling of cardiac stromal populations and microenvironments in systemic sclerosis-associated primary myocardial involvement
- Thrombotic microangiopathy in a patient with systemic lupus erythematosus and systemic sclerosis overlap syndrome: a case report and review of the literature
BibTeX
@article{carvalho2026efficacy,
title = {{Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis}},
author = {Jozélio Freire de Carvalho and Roberto Paulo Correia de Araujo and Maria Giovanna Danieli and Yehuda Shoenfeld},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1949145},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949145/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis
AU - Jozélio Freire de Carvalho
AU - Roberto Paulo Correia de Araujo
AU - Maria Giovanna Danieli
AU - Yehuda Shoenfeld
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1949145
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949145/full
AB - Background: Systemic sclerosis (SSc) is a complex autoimmune disease mainly characterized by progressive fibrosis affecting the skin and internal organs. Although several immunosuppressive and targeted therapies are currently available, many patients continue to experience refractory manifestations. Intravenous immunoglobulin (IVIG) has been increasingly used as an adjunctive treatment in selected cases; however, its efficacy across different disease manifestations remains incompletely defined. Objective: To systematically evaluate the efficacy and safety of IVIG in patients with systemic sclerosis and to quantitatively synthesize available evidence regarding its effects on skin involvement, gastrointestinal manifestations, and inflammatory myopathy. Methods: A systematic review and meta-analysis were conducted according to PRISMA 2020 guidelines. MEDLINE/PubMed, Embase, LILACS, and the Cochrane Library were searched from January 1966 to May 2026. Studies evaluating IVIG in adult patients with systemic sclerosis were included. Randomized controlled trials, observational cohorts, pilot studies, and case series were eligible. Quantitative synthesis was performed using random-effects models and standardized mean differences (SMDs) with 95% confidence intervals (CIs). Results: Eleven studies were included in the systematic review. Six studies provided sufficient quantitative data for the meta-analysis of skin involvement, three for gastrointestinal outcomes, and two for muscle outcomes. The most common indications for IVIG therapy were cutaneous fibrosis, inflammatory myopathy, gastrointestinal involvement, and refractory musculoskeletal manifestations. Meta-analysis demonstrated a significant improvement in skin involvement assessed by the modified Rodnan Skin Score (SMD −0.59, 95% CI −0.95 to −0.22; p = 0.0019; I ² = 78.0%). Gastrointestinal manifestations also improved significantly (SMD −0.73, 95% CI −1.16 to −0.29; p = 0.0012; I ² = 0%). For inflammatory myopathies, a limited quantitative synthesis of two studies showed a significant reduction in creatinekinase levels (SMD −0.53, 95% CI −0.80 to −0.26; p < 0.001). Across studies, IVIG was well tolerated, and serious adverse events were uncommon. Conclusion: IVIG was associated with improvements in several clinical outcomes, particularly in observational studies, including skin fibrosis, gastrointestinal manifestations, and inflammatory myopathies. However, the only randomized placebo-controlled trial did not demonstrate significant short-term improvement in skin involvement at its primary endpoint. The available evidence suggests a potential adjunctive role for IVIG in selected patients.
SN - 1664-3224
ER -